Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001609351-17-000114
Filing Date
2017-11-07
Accepted
2017-11-07 16:05:50
Documents
59
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q spark-201793010xq.htm 10-Q 1123632
2 EXHIBIT 31.1 spark-2017930exx311.htm EX-31.1 21900
3 EXHIBIT 31.2 spark-2017930exx312.htm EX-31.2 21899
4 EXHIBIT 32.1 spark-2017930exx321.htm EX-32.1 7116
5 EXHIBIT 32.2 spark2017930ex-322.htm EX-32.2 6995
  Complete submission text file 0001609351-17-000114.txt   4352184

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT once-20170930.xml EX-101.INS 587188
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT once-20170930.xsd EX-101.SCH 34070
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT once-20170930_cal.xml EX-101.CAL 59404
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT once-20170930_def.xml EX-101.DEF 187837
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT once-20170930_lab.xml EX-101.LAB 507684
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT once-20170930_pre.xml EX-101.PRE 310341
Mailing Address 3737 MARKET STREET SUITE 1300 PHILADELPHIA PA 19104
Business Address 3737 MARKET STREET SUITE 1300 PHILADELPHIA PA 19104 888-772-7560
Spark Therapeutics, Inc. (Filer) CIK: 0001609351 (see all company filings)

EIN.: 462654405 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36819 | Film No.: 171183395
SIC: 2836 Biological Products, (No Diagnostic Substances)